pneumococcal polysaccharide conjugate + pneumococcal polysaccharide

This combination refers to the therapeutic use of both pneumococcal polysaccharide conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPSV) to prevent infections caused by *Streptococcus pneumoniae*. PCVs, such as PCV13, PCV15, and PCV20, consist of purified capsular polysaccharides from specific serotypes covalently linked to a carrier protein (typically CRM197). This conjugation converts the polysaccharide into a T-cell dependent antigen, inducing high-affinity antibodies, mucosal immunity, and long-term immunological memory, making it effective in infants and for reducing nasopharyngeal carriage. In contrast, PPSVs, most notably the 23-valent PPSV23, contain purified capsular polysaccharides without a carrier protein. These elicit a T-cell independent immune response that provides broader coverage against a larger number of serotypes but lacks the memory response and effectiveness in young children. The combination or sequential administration of these two vaccine types is a standard clinical strategy in adults aged 65 and older and immunocompromised individuals to maximize both the potency and the breadth of protection against invasive pneumococcal disease (IPD) and pneumonia.

Brand names

Prevnar 13Prevnar13Prevnar-13Prevnar 20Prevnar20Prevnar-20VaxneuvancePneumovax 23Pneumovax23Pneumovax-23SynflorixPneumosil

Other names

PCV + PPSVpneumococcal conjugate vaccine plus pneumococcal polysaccharide vaccinepneumococcal vaccine, polyvalent and conjugateJ07AL52J-07AL52J 07AL52